Quadrant Biosciences

Quadrant Biosciences

Growth Stage

We develop novel, saliva based tests for Autism, COVID-19 and Parkinson's.

We develop novel, saliva based tests for Autism, COVID-19 and Parkinson's.

Overview

Raised to Date: Raised: $411,608

Total Commitments ($USD)

Platform

Wefunder

Start Date

08/26/2020

Close Date

02/18/2021

Min. Goal
$50,000
Max. Goal
$1,070,000
Min. Investment

$100

Security Type

Convertible Note

Series

Series A

SEC Filing Type

RegCF    Open SEC Filing

Valuation Cap

Uncapped

Discount

20%

Rolling Commitments ($USD)

Status
Funded
Reporting Date

02/27/2021

Days Remaining
Funded
% of Min. Goal
Funded
% of Max. Goal
Funded
Likelihood of Max
Funded
Avg. Daily Raise

$2,352

# of Investors

492

Momentum
Funded
Create a free account today to gain access to KingsCrowd analytics.
Logos provided by Clearbit
Year Founded

2015

Industry

Healthcare & Pharmaceuticals

Tech Sector

HealthTech

Distribution Model

B2B

Margin

Medium

Capital Intensity

High

Location

Syracuse, New York

Business Type

High Growth

Company Website

Quadrant Biosciences is raising funds on Wefunder. The company has launched the world’s first saliva test for autism and is developing a pipeline of products, including tests for schizophrenia, anorexia nervosa, concussion, and Parkinson’s disease. The test for autism, The Clarifi ASD Test, is a game-changer in autism diagnosis and indicates the probability of a child having autism spectrum disorder. Quadrant Biosciences was founded by Richard Uhlig and has raised over $30 million in previous rounds of financing. The current round of crowdfunding has a minimum goal of $50,000 and a maximum goal of $1,070,000, and the proceeds will be used in developing more tests. Quadrant Biosciences has multiple international research partnerships and is working on developing a rapid saliva test for COVID-19.

Summary Profit and Loss Statement

Most Recent Year Prior Year

Revenue

$413,811

$115,778

COGS

$426,512

$192,281

Tax

$-204,267

$-237,516

 

 

Net Income

$-7,296,264

$-6,943,093

Summary Balance Sheet

Most Recent Year Prior Year

Cash

$1,289,474

$4,945,726

Accounts Receivable

$12,653

$24,077

Total Assets

$8,672,233

$9,091,991

Short-Term Debt

$736,722

$650,959

Long-Term Debt

$5,349,064

$5,398,139

Total Liabilities

$6,085,786

$6,049,098
Financials as of: 08/26/2020
Create a free account today to gain access to KingsCrowd analytics.

Raise History

Offering Name Close Date Platform Valuation/Cap Total Raised Security Type Status Reg Type
Quadrant Biosciences 02/17/2021 Wefunder - $411,608 Convertible Note Funded RegCF
Quadrant Biosciences 08/14/2020 Wefunder $266,000,000 $1,004,649 Equity - Common Funded RegA+
Create a free account today to gain access to KingsCrowd analytics.

Price per Share History

Note: Share prices shown in earlier rounds may not be indicative of any stock splits.

Valuation History

Revenue History

Note: Revenue data points reflect the latest of either the most recent fiscal year's financials, or updated revenues directly from the founder, at each raise's close date.

Employee History

Upgrade to gain access

Pay Monthly
Annually (Save 17%)

Edge

$25 /month
billed annually
Free portfolio tracking, data-driven ratings, AI analysis and reports
Plan Includes:
Everything in Free, plus
Company specific KingsCrowd ratings and analyst reports
Deal explorer and side-by-side comparison
Startup exit and failure tracking
Startup market filters and historical industry data
Advanced company search ( with ratings)
Get Edge Annual
Already a member? Log in here.
Founders: enhance your startup's credibility on KingsCrowd. Create an account to claim this raise page.
Add to portfolio
Quadrant Biosciences on Wefunder
Platform: Wefunder
Security Type: Convertible Note

Follow company

Follow Quadrant Biosciences on Wefunder
View on Wefunder (Closed)
Deal Analytics
Deal Considerations

Buy Quadrant Biosciences's Deal Report

Warning: according to the close date for this deal, Quadrant Biosciences may no longer be accepting investments.

Quadrant Biosciences Deal Report

Get KingsCrowd’s comprehensive report on Quadrant Biosciences including:

  • How our proprietary algorithm rates their current capital raise (1-5 stars)
  • Detailed price, market, team, differentiators, performance, and risk ratings
  • Whether Quadrant Biosciences is undervalued or overvalued
  • Scores on the founding team and key personnel's background and expertise

Buy the Quadrant Biosciences deal report for only $10!

Email address:
Looking to buy more than one deal report? Get unlimited reports by upgrading to Edge